The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Me too! i'm trying to get the timing right with a riser that i have a holding in!
Fair enough guys, it was just a thought. After starting the day feeling a bit down, I am now seriously thinking about buying in again at these levels.
That interview is fantastic. Calm, considered and concise. Thanks Sharesting.
Mike29, if you read the link posted this morning on another trial of Interferon 1B administered by IV it showed benefit on discharge (14 days) and Mortality (28 days) rates.
https://www.medrxiv.org/content/10.1101/2020.05.28.20116467v1
Mike they will not hold onto the data.
They have to release it. All I’m saying is the more data they can present to the FDA and MHRA the better. Hence the early finish on COPD.
If there is a possibility that the hospital trial may not be as successful as the home trial, given the broad assumption that the earlier the drug is administered the better, then would it be better if both results are announced at the same time. Even though this would push things back time wise. This is purely from a point of view of not destroying sentiment towards Synairgen and the drug itself. Just a thought.
It’s clear Prof Holgate thinks SNG001 is will boost immunity (lung health) and another drug will target the virus.
Combined you have a clear treatment.
Very exciting listening to these experts. Notice how certain posters always dismiss, ignore or don’t listen to these experts... very lazy.
Great interview, but don't forget it's dated 27th May 2020
Multi drug applications ??
Can you be precise, please ?
Sharesting - I remember you forecasting they would reduce to 10% then stop. Even a broken Clock is right twice a day.
Yeah I agree, as part of the hospital trial, they will be a range of timings of administration after onset of symptoms. Hopefully the data will show that those patients who managed to be administrated earlier improved quicker, which will be further validated by the home trial.
Forest I think it will be patient specific. As he said the drug works at best as early treatment. I think we should see a positive from hospital trials, but the mega results will come from the at home trials. I think this is why they want to open COPD trials. As it will help with their multi drug applications!!
Prof Holgate seems very optimistic about the home trial. Is it fair of me to conclude that he isn't as optimistic of the hospital trial efficacy because of the timing of administration ? Should we read into this?
Right
Have listened to the Prof Holgate interview 3 times. So much information in there. Combine that with Richard’s updates, things are hotting up !
I forecast a Lansdowne TR1 confirming under 3% will land.
Let’s see if I’m write.
Can someone show the research to the sp please.
My main frustration is I cant really buy anymore shares at the moment!
Interferon Beta 1 - injection comes with side effects.
Interferon Beta 1 - via nebuliser side effects low.
Rapid approval was given due to safety, freedom side effects and also plausible biological mechanism which they could give regulatory authorities to how such an agent would increase the immunity of an individual infected with C-19.
Asthma and COPD study demonstrates the earlier drug is given the less viral spread in the lung. Same should apply to C-19.
Mass manufacturing- servers organisations lined up around the world to make the material very rapidly!
At home trial is the one they are most excited about.
Very precise way to deliver the drug.
SNG001 strengthens the host response to the virus. If it’s combined with another drug that targets the virus.
Very interesting interview. Just shows you the amount of discussions happening behind the scene at Synairgen!